Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | CCNC | P24863 | 2/20 | 0.47 |
| ▸ | CDK8 | P49336 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222255 | 0.83 | CHEK1 (0.70) | MKNK1MKNK2MAP4K4CHEK1PIM1 | |
| SCHEMBL844281 | 0.81 | LRRK2 (0.61) | MKNK1MKNK2LRRK2CCNCCDK8 | |
| SCHEMBL16196117 | 0.81 | DHODH (0.70) | MAP4K4DHODHRXRARXRBCTRC | |
| SCHEMBL29627308 | 0.78 | KMO (0.54) | MKNK1MKNK2MAP4K4CHEK1PIM1 | |
| SCHEMBL21816369 | 0.78 | KMO (0.54) | MKNK1MKNK2MAP4K4CHEK1PIM1 | |
| SCHEMBL1495453 | 0.78 | DHODH (0.70) | MAP4K4DHODHRXRARXRBCTRC | |
| Hydrochloric Acid SCHEMBL29971276 | 0.77 | KMO (0.53) | MKNK1MKNK2MAP4K4CHEK1PIM1 | |
| SCHEMBL345756 | 0.76 | LOXL2 (0.50) | MKNK1MKNK2MAP4K4CHEK1PIM1 | |
| SCHEMBL4156643 | 0.76 | KDM4C (0.51) | MAP4K4DHODHRXRARXRBCTRC | |
| SCHEMBL31705513 | 0.76 | MKNK1 (0.61) | MKNK1MKNK2MAP4K4CHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896439-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8440673-B2 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2234976-B1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-2234976-A1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-07-02 | — | — | US | disclosed |
| WO-2009077367-A1 | NOVEL PYRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170873-A1 | Pyrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | MKNK1 3426/4885MKNK2 2405/4885MAP4K4 3215/4885 |
| US-20130289025-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | MKNK1 3426/4885MKNK2 2405/4885MAP4K4 3215/4885 |
| US-20170096416-A1 | PYRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX7 | MKNK1 3426/4885MKNK2 2405/4885MAP4K4 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.